LogoPeqSERPE
logoCabeceraNinos

Hemos leído sobre ... Vacunación en enf. reumáticas

Última actualización: 7 abril 2022
 
  
 
MARZO 2022
  • Cuadros EN, Calzada-Hernández J, Clemente D, Martín SG, Silveira LF, Lirola-Cruz MJ, Tagarro A, Lovillo MC, Rueda RMA, López AL, Aritziturri MS, Calvo C.
    Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening).
    Eur J Pediatr. 2022 Mar 8. doi: 10.1007/s00431-022-04418-7. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35258699/

  • Fragoulis GE, Karamanakos A, Arida A, Bournia VK, Evangelatos G, Fanouriakis A, Fragiadaki K, Kravvariti E, Laskari K, Panopoulos S, Papazoglou N, Pappa M, Tektonidou MGG, Sfikakis PP.
    Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases.
    RMD Open. 2022 Mar;8(1):e002279. doi: 10.1136/rmdopen-2022-002279.
    https://pubmed.ncbi.nlm.nih.gov/35246472/

  • Aikawa NE, Kupa LVK, Medeiros-Ribeiro AC, Saad CGS, Yuki EFN, Pasoto SG, et al.
    Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases.
    Ann Rheum Dis. 2022 Mar 11:annrheumdis-2021-222096. doi: 10.1136/annrheumdis-2021-222096. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35277389/

  • Mori S, Ueki Y, Ishiwada N.
    Impact of Janus Kinase Inhibitors on Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine in Patients with Rheumatoid Arthritis.
    Mod Rheumatol. 2022 Mar 26:roac029. doi: 10.1093/mr/roac029. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35348759/

  • Troldborg A, Thomsen MK, Bartels LE, Andersen JB, Vils SR, Mistegaard CE, et al.
    Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases.
    J Rheumatol. 2022 Mar 1:jrheum.211152. doi: 10.3899/jrheum.211152. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35232803/

  
FEBRERO 2022
  • Heshin-Bekenstein M, Ziv A, Toplak N, Hagin D, Kadishevich D, Butbul YA, Saiag E, Kaufman A, Shefer G, Sharon O, Pel S, Elkayam O, Uziel Y.
    Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
    Rheumatology (Oxford). 2022 Feb 18:keac103. doi: 10.1093/rheumatology/keac103. 
    https://pubmed.ncbi.nlm.nih.gov/35179569/

ENERO 2022
  • Atagündüz P, Keser G, Soy M.
    Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review.
    Front Immunol. 2022 Jan 27;12:734279. doi: 10.3389/fimmu.2021.734279. 
    https://pubmed.ncbi.nlm.nih.gov/35154066/

  • Marty PK, Van Keulen VP, Erskine CL, Shah M, Hummel A, Stachowitz M, Fatis S, Granger D, Block MS, Duarte-García A, Warrington KJ, Theel ES, Zhou X, Zeng H, Specks U, Escalante P, Peikert T.
    Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
    Front Immunol. 2022 Jan 28;13:834981. doi: 10.3389/fimmu.2022.834981.
    https://pubmed.ncbi.nlm.nih.gov/35154159/

DICIEMBRE 2021
  • Keller M, Pittet LF, Zimmermann P.
    Immunogenicity and safety of routine vaccines in children and adolescents with rheumatic diseases on immunosuppressive treatment - a systematic review.
    Eur J Pediatr. 2021 Dec 22;1-34. doi: 10.1007/s00431-021-04283-w. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34936010/

  • Degrava Sampaio-Barros P, Medeiros-Ribeiro AC, Luppino-Assad AP, Miossi R, Carriço da Silva H et al.
    SARS-CoV-2 vaccine in patients with systemic sclerosis: Impact of disease subtype and therapy.
    Rheumatology (Oxford). 2021 Dec 11;keab886. doi: 10.1093/rheumatology/keab886. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34894235/ 

  • Tzioufas AG, Bakasis AD, Goules AV, Bitzogli K et al.
    A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
    J Autoimmun. 2021 Dec;125:102743. doi: 10.1016/j.jaut.2021.102743. Epub 2021 Oct 28.
    https://pubmed.ncbi.nlm.nih.gov/34757289/

NOVIEMBRE 2021
  • Dimopoulou D, Vartzelis G, Dasoula F, Tsolia M, Maritsi D.
    Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors.
    Ann Rheum Dis. 2021 Nov 29:annrheumdis-2021-221607. doi: 10.1136/annrheumdis-2021-221607. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34844930/ 

 
AGOSTO 2021
  • Chiang TP, Connolly CM, Ruddy JA, Boyarsky BJ, Alejo JL, Werbel WA, Massie A, Christopher-Stine L, Garonzik-Wang J, Segev DL, Paik JJ.
    Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases.
    Ann Rheum Dis. 2021 Aug 24:annrheumdis-2021-221145. doi: 10.1136/annrheumdis-2021-221145. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34429320/

  • Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, et al.
    Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.
    Lancet Rheumatol. 2021 Aug 6. doi: 10.1016/S2665-9913(21)00222-8. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34396154/

  • Prendecki M, Clarke C, Edwards H, McIntyre S, Mortimer P, Gleeson S, et al.
    Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.
    Ann Rheum Dis. 2021 Aug 6:annrheumdis-2021-220626. doi: 10.1136/annrheumdis-2021-220626. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34362747/

  • Wong PKK, Lahiri M, Lye DC, Johnson D, Charles PGP.
    A vaccination update for rheumatologists-SARS-CoV-2, influenza and herpes zoster.
    Int J Rheum Dis. 2021 Aug;24(8):979-983. doi: 10.1111/1756-185X.14179.
    https://pubmed.ncbi.nlm.nih.gov/34350721/

 
JULIO 2021
  • Rollet-Cohen V, Mirete J, Dingulu G, Hofer F, Hofer M, Woerner A, Dommergues MA, Hentgen V.
    Suboptimal vaccination coverage of recommended vaccines among French children with recurrent autoinflammatory fever syndromes: a study from the Juvenile Inflammatory Rheumatism cohort.
    Clin Rheumatol. 2021 Jul;40(7):2855-2864. doi: 10.1007/s10067-020-05553-y. Epub 2021 Jan 13. PMID: 33439385.
    https://pubmed.ncbi.nlm.nih.gov/33439385/

 
JUNIO 2021
  • Jeffrey R Curtis, Sindhu R Johnson, Donald D Anthony et al.
    American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2
    Arthritis Rheumatol. 2021 Jun 15. doi: 10.1002/art.41877. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34128356/

  • Amelia Santosa, Chuanhui Xu, Thaschawee Arkachaisri et al.
    Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists
    Int J Rheum Dis. 2021 Jun;24(6):746-757. doi: 10.1111/1756-185X.14107. Epub 2021 May 10
    https://pubmed.ncbi.nlm.nih.gov/33973379/

  • Victoria Furer, Tali Eviatar, Devy Zisman et al.
    Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
    Ann Rheum Dis. 2021 Jun 14;annrheumdis-2021-220647. doi: 10.1136/annrheumdis-2021-220647. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34127481/

  • Yolanda Braun-Moscovici, Marielle Kaplan, Maya Braun et al.
    Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
    Ann Rheum Dis. 2021 Jun 18;annrheumdis-2021-220503. doi: 10.1136/annrheumdis-2021-220503. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34074678/

 
MAYO 2021
  • Hazlewood GS, Pardo Pardo J, Barnabe C, Schieir O, Barber CEH, Bernatsky S, Colmegna I, Hitchon C, Loeb M, Mertz D, Proulx L, Richards DP, Scuccimarri R, Tugwell P, Schünemann HJ, Mirza RD, Zhou AL, Nikolic RPA, Thomas M, Chase H, Ejaredar M, Nieuwlaat R.
    Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases.
    J Rheumatol. 2021 May 15:jrheum.210288. doi:10.3899/jrheum.210288
    https://pubmed.ncbi.nlm.nih.gov/33993119/

MARZO 2021
  • Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al.
    American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases - Version 1.
    Arthritis Rheumatol. 2021 Mar 17. doi: 10.1002/art.41734. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/33728796/

  • Arnold J, Winthrop K, Emery P.
    COVID-19 vaccination and antirheumatic therapy.
    Rheumatology (Oxford). 2021 Mar 12:keab223. doi: 10.1093/rheumatology/keab223. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/33710296/ 

  • Park JK, Lee EB, Shin K, Sung YK, Kim TH, Kwon SR, et al; Korean College of Rheumatology Task Force for COVID-19 Vaccine Guidance for Patients with Autoimmune.
    COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.
    J Korean Med Sci. 2021 Mar 29;36(12):e95. doi: 10.3346/jkms.2021.36.e95.
    https://pubmed.ncbi.nlm.nih.gov/33783147/

  • Soy M, Keser G, Atagunduz P, Mutlu MY, Gunduz A, Koybaşi G, Bes C.
    A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review.
    Clin Rheumatol. 2021 Mar 22:1-13. doi: 10.1007/s10067-021-05700-z. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/33751280/

  • Jensen L, Nielsen S, Christensen AE, Pedersen FK, Trebbien R, Kølsen Fischer T, et al.
    Response to influenza vaccination in immunocompromised children with rheumatic disease: a prospective cohort study.
    Pediatr Rheumatol Online J. 2021 Mar 12;19(1):26. doi: 10.1186/s12969-021-00518-0.
    https://pubmed.ncbi.nlm.nih.gov/33712043/

     

  • Constantinou CA, Ziogas DC, Venetsanopoulou A, Gamaletsou MN, Koutsogeorgopoulou L, Barbouni A, Tzioufas AG, Sipsas NV.
    A clinical audit of pneumococcal vaccination among patients with autoimmune rheumatic diseases living in Greece: The power of awareness.
    Vaccine. 2021 Mar 12;39(11):1593-1597. doi: 10.1016/j.vaccine.2021.02.009. 
    https://pubmed.ncbi.nlm.nih.gov/33610375/

 
FEBRERO 2021
ENERO 2021
  • Tse HN, Borrow R, Arkwright PD.
    Immune Response and Safety of Viral Vaccines in Children with Autoimmune Diseases on Immune Modulatory Drug Therapy.
    Expert Rev Vaccines. 2021 Jan 28:1-13. doi: 10.1080/14760584.2021.1875825. Epub ahead of print. PMID: 33507119.
    https://pubmed.ncbi.nlm.nih.gov/33507119/

DICIEMBRE 2020
  • Grein IHR, Pinto NBF, Groot N, Martins CB, Lobo A, Aikawa NE, Barbosa C, Terreri MT, da Fraga ACM, de Oliveira SKF, Sztajnbok F, Paim Marques LB, Islabão AG, Appenzeller S, Bica B, de Oliveira Sato J, Magalhães CS, Ferriani V, Pasmans H, Schepp R, van der Klis F, de Roock S, Wulffraat N, Pileggi GS.
    Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study.
    Pediatr Rheumatol Online J. 2020 Nov 11;18(1):87.
    https://pubmed.ncbi.nlm.nih.gov/33176806/

  • Peracchi OA, Nicácio AAM, Yamada J, Len CA, Moraes-Pinto MI, Terreri MT.
    Adequate tetanus but poor diphtheria and pertussis response to a Tdap booster in adolescents with juvenile systemic lupus erythematosus.
    Lupus. 2020 Nov 16:961203320973263. doi: 10.1177/0961203320973263
    https://pubmed.ncbi.nlm.nih.gov/33197362/

SEPTIEMBRE 2020
  • Ben Nessib D, Fazaa A, Miladi S, Sellami M, Ouenniche K, Souabni L, Kassab S, Chekili S, Ben Abdelghani K, Laatar A.
    Do immunosuppressive agents hamper the vaccination response in patients with rheumatic diseases? A review of the literature.
    Therapie. 2020 Sep 3:S0040-5957(20)30148-7. doi: 10.1016/j.therap.2020.08.002. Online ahead of print
    https://pubmed.ncbi.nlm.nih.gov/32951867/

  • Figueroa-Parra G, Esquivel-Valerio JA, Santoyo-Fexas L, Moreno-Salinas A, Gamboa-Alonso CM, De Leon-Ibarra AL, Galarza-Delgado DA.
    Knowledge and attitudes about influenza vaccination in rheumatic diseases patients.
    Hum Vaccin Immunother. 2020 Sep 29:1-6. doi: 10.1080/21645515.2020.1816108. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/32991221/

  • Bühler S, Jaeger VK, Eperon G, Furrer H, Fux CA, Jansen S, et al.
    Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study1.
    J Travel Med. 2020 Sep 26;27(6):taaa126. doi: 10.1093/jtm/taaa126.
    https://pubmed.ncbi.nlm.nih.gov/32729905/

 
AGOSTO 2020
  • Alfayadh NM, Gowdie PJ, Akikusa JD, Easton ML, Buttery JP.
    Vaccinations Do Not Increase Arthritis Flares in Juvenile Idiopathic Arthritis: A Study of the Relationship between Routine Childhood Vaccinations on the Australian Immunisation Schedule and Arthritis Activity in Children with Juvenile Idiopathic Arthritis.
    Int J Rheumatol. 2020 Aug 4;2020:1078914. doi: 10.1155/2020/1078914.
    https://pubmed.ncbi.nlm.nih.gov/32831849/

  • Welzel T, Wörner A, Heininger U.Z.
    Travel vaccinations in rheumatic diseases : Specific considerations in children and adults.
    Rheumatol. 2020 Aug 26. doi: 10.1007/s00393-020-00852-w.
    https://pubmed.ncbi.nlm.nih.gov/32845394/
 
JULIO 2020
  • Rotstein Grein IH, Pinto NF, Lobo A, Groot N, Sztajnbok F, da Silva CAA, Paim Marques LB, Appenzeller S, Islabão AG, Magalhães CS, de Almeida RG, Bica B, Fraga M, da Fraga ACM, Dos Santos MC, Robazzi T, Terreri MTR, Bandeira M, Pasmans H, Schepp R, van der Klis F, de Roock S, Wulffraat N, Pileggi G.
    Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study.
    Lupus. 2020 Jul;29(8):934-942. doi: 10.1177/0961203320928406. Epub 2020 Jun 5.
    https://pubmed.ncbi.nlm.nih.gov/32501172/

 
MAYO 2020
 
MARZO 2020
  • Nakafero G, Grainge MJ, Myles PR, Mallen CD, Zhang W, Doherty M, Nguyen-Van-Tam JS, Abhishek A.
    Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs.
    Rheumatology (Oxford). 2020 Mar 11. pii: keaa078. doi: 10.1093/rheumatology/keaa078. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32160295
 
FEBRERO 2020
  • Bizjak M, Blazina Š, Zajc Avramovic M, Markelj G, Avcin T, Toplak N.
    Vaccination coverage in children with rheumatic diseases.
    Clin Exp Rheumatol. 2020 Jan-Feb;38(1):164-170. Epub 2019 Oct 2.
    https://www.ncbi.nlm.nih.gov/pubmed/31577215
  • Brunner HI, Tzaribachev N, Cornejo GV, Joos R, Gervais E, Cimaz R, Calvo Penadés I, Cuttica R, Lutz T, Quartier P, Gandhi Y, Nys M, Wong R, Martini A, Lovell DJ, Ruperto N; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation.
    Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5?years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept.
    Pediatr Rheumatol Online J. 2020 Feb 22;18(1):19. doi: 10.1186/s12969-020-0410-x.
    https://www.ncbi.nlm.nih.gov/pubmed/32087715
 
ENERO 2020
  • Uziel Y, Moshe V, Onozo B, Kulcsár A, Tróbert-Sipos D, Akikusa JD, Salviato Pileggi G, Maritsi D, Kasapcopur O, Rodrigues M, Smerla R, Rigante D, Makay B, Atsali E, Wulffraat N, Toplak N; PReS working party of Vaccination Study Group.
    Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection.
    Vaccine. 2020 Jan 24. pii: S0264-410X(20)30052-9. doi: 10.1016/j.vaccine.2020.01.037. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/31987692
 
JULIO 2019
  •  Qendro T, de la Torre ML, Panopalis P, Hazel E, Ward BJ, Colmegna I, Hudson M.
    Suboptimal immunization coverage among Canadian rheumatology patients in routine clinical care.
    J Rheumatol. 2019 Jul 15. pii: jrheum.181376. doi: 10.3899/jrheum.181376. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/?term=31308211
 
MARZO 2018
  • Speth F, Hinze CH, Andel S, Mertens T, Haas JP.
    Varicella-zoster-virus vaccination in immunosuppressed children with rheumatic diseases using a pre-vaccination check list.
    Pediatr Rheumatol Online J. 2018 Mar 2;16(1):15.
    https://www.ncbi.nlm.nih.gov/pubmed/29499726

     

  • Jeyaratnam J, Ter Haar NM, Lachmann HJ, Kasapcopur O, Ombrello AK, Rigante D, Dedeoglu F, Baris EH, Vastert SJ, Wulffraat NM, Frenkel J.
    The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey.
    Pediatr Rheumatol Online J. 2018 Mar 21;16(1):19. doi: 10.1186/s12969-018-0235-z.
    https://www.ncbi.nlm.nih.gov/pubmed/29562920
PATROCINADORES